Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events
Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events
复制标题
与达拉非尼加曲美替尼联合治疗相关的纤溶标志物和降钙素原显着升高:不常见的不良事件
DOI:
10.1111/1346-8138.15163
复制
发表时间:
2019
期刊:
影响因子:
--
通讯作者:
Fujisawa Yasuhiro
中科院分区:
文献类型:
--
作者:
Nakamura Yoshiyuki;Ishizuki Shoichiro;Iwasaki Riko;Okiyama Naoko;Ishitsuka Yosuke;Matsumura Yutaka;Tanaka Ryota;Maruyama Hiroshi;Watanabe Rei;Fujisawa Yasuhiro
影响因子:
45.3
作者:
R. R. H. van den Brom;A. Mäkelburg;C. Schröder;E. D. de Vries;G. Hospers
通讯作者:
G. Hospers